Abstract | PURPOSE: PATIENTS AND METHODS: This was a 2-part multicenter study of panitumumab 2.5 mg/kg weekly with irinotecan, 5-fluorouracil (5-FU), and leucovorin. Part 1 used bolus 5-FU (IFL), and part 2 used infusional 5-FU (FOLFIRI). Tolerability (measured by grade 3/4 diarrhea) was the primary endpoint. Objective response, progression-free survival, overall survival, and safety were also examined. RESULTS: Nineteen patients in part 1 and 24 patients in part 2 received panitumumab plus chemotherapy. Grade 3/4 diarrhea occurred in 11 patients (58%) in part 1 and 6 patients (25%) in part 2. All patients had a skin-related toxicity (no grade 4 events). Objective response rates were 46% in part 1 and 42% in part 2. Disease control rates were 74% in part 1 and 79% in part 2. Median progression-free survival (95% confidence interval) was 5.6 months (4.4-8.3 months) for part 1 and 10.9 months (7.7-22.5 months) for part 2. Median overall survival (95% confidence interval) was 17 months (13.7 months to not estimable) for part 1 and 22.5 months (14.4 months to not estimable) for part 2. CONCLUSION: In patients with mCRC, panitumumab/IFL was not well tolerated. Panitumumab/FOLFIRI was well tolerated, showed promising activity, and is undergoing further investigation.
|
Authors | Jordan Berlin, James Posey, Simon Tchekmedyian, Eddie Hu, David Chan, Imtiaz Malik, Liqiang Yang, Rafael G Amado, J Randolph Hecht |
Journal | Clinical colorectal cancer
(Clin Colorectal Cancer)
Vol. 6
Issue 6
Pg. 427-32
(Mar 2007)
ISSN: 1533-0028 [Print] United States |
PMID | 17531105
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Vitamin B Complex
- Panitumumab
- Irinotecan
- ErbB Receptors
- Leucovorin
- Fluorouracil
- Camptothecin
|
Topics |
- Adenocarcinoma
(drug therapy, enzymology, pathology)
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Camptothecin
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Colorectal Neoplasms
(drug therapy, enzymology, pathology)
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Fluorouracil
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Irinotecan
- Leucovorin
(administration & dosage, adverse effects, therapeutic use)
- Male
- Middle Aged
- Neoplasm Metastasis
- Panitumumab
- Vitamin B Complex
(administration & dosage, adverse effects)
|